《大行報告》美銀證券上調昭衍新藥(06127.HK)目標價至204.3元 評級「買入」
美銀證券發表研究報告指,昭衍新藥(06127.HK)首季業績符合預期,收入按年增長29.9%,毛利增長36.6%,毛利率按年提升2.5個百分點,撇除匯兌收益及非經常性損益後,經調整淨利潤按年增長46%至2,150萬元人民幣。
該行指,昭衍新藥收入及盈利內生增長率已分別達到49%及65%,撇除收購Biomere的因素後,首季經調整淨利潤內生增長率更逾倍,認為毛利率表現理想,預期加上Biomere,未來增長勢頭強勁。
美銀指,蘇州生產設施明年將再擴建9,000平方米,上調長期銷售預測,預計2021至2023年銷售額將達到15.63億、22.55億及31.55億元人民幣,目標價將由184.3元升至204.3元,重申「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.